Pipeline
| Research | Pre-clinical development | Phase I | Phase II |
|---|---|---|---|
|
ADC-1013* (CD40)
|
|||
|
ATOR-1015 (OX40 - CTLA-4)
|
|||
|
ATOR-1017 (4-1BB)
|
|||
|
ALG.APV-527* (4-1BB - 5T4)
|
|||
|
(TNFRSF – ND)
|
|||
TNFRSF: Tumor Necrosis Factor Receptor Superfamily
ND: Not Disclosed
*ADC-1013 is partnered with Janssen Biotech Inc. and developed as JNJ-7107. ALG.APV-527 is based on Alligator’s first generation bispecific antibody, ATOR-1016, and is co-developed with Aptevo Therapeutics